Ivosidenib for the treatment of IDH1-mutant glioma, grades 2–4: Tolerability, predictors of response, and outcomes
In this large cohort of IDHm glioma patients, ivosidenib was well tolerated. Our results support the use of IDHi therapy in patients with grade 2 or 3 astrocytoma or oligodendroglioma and highlight limited effectiveness in patients with enhancing disease.
Authors
- L. Nicolas Gonzalez Castro (ORCID: https://orcid.org/0000-0001-7699-5188)
- Julie J. Miller (ORCID: https://orcid.org/0000-0002-1288-593X)
- Daniel P. Cahill (ORCID: https://orcid.org/0000-0003-2552-6546)
- Thomas F. Flood (ORCID: https://orcid.org/0000-0001-9653-0871)
- Patrick Y. Wen (ORCID: https://orcid.org/0000-0002-0774-7700)
- Samuel K. McBrayer (ORCID: https://orcid.org/0000-0001-9361-675X)
- Isabel Arrillaga‐Romany (ORCID: https://orcid.org/0000-0001-5951-1225)
- Gilbert Youssef (ORCID: https://orcid.org/0000-0001-6109-7692)
- Matthew N. DeSalvo (ORCID: https://orcid.org/0000-0002-2386-689X)
- Zhou Lan
- Diana D. Shi (ORCID: https://orcid.org/0000-0002-6626-5277)
- Eudocia Q. Lee (ORCID: https://orcid.org/0000-0003-3355-5179)
- Elmira Hassanzadeh (ORCID: https://orcid.org/0000-0003-4460-698X)
- Vihang Nakhate (ORCID: https://orcid.org/0000-0002-2941-9740)
- Wenya Linda Bi (ORCID: https://orcid.org/0000-0002-4635-0247)
- Ian Pan (ORCID: https://orcid.org/0000-0002-0650-6614)
- Jörg Dietrich (ORCID: https://orcid.org/0000-0001-8291-0136)
- J. Lauer (ORCID: https://orcid.org/0009-0007-9475-512X)
- Rifaquat Rahman (ORCID: https://orcid.org/0000-0002-9443-1797)
- Ugonma Nnenna Chukwueke (ORCID: https://orcid.org/0000-0003-0598-9535)
- Justin T. Jordan (ORCID: https://orcid.org/0000-0001-6198-817X)
- David A. Reardon (ORCID: https://orcid.org/0000-0001-6674-0157)
- Raymond Y. Huang (ORCID: https://orcid.org/0000-0001-7661-797X)
- Tracy T. Batchelor (ORCID: https://orcid.org/0000-0001-7568-6607)
- Lakshmi Nayak
- Tyler Lanman (ORCID: https://orcid.org/0000-0001-8746-282X)
- Juan Pablo Ospina (ORCID: https://orcid.org/0000-0003-0556-6364)
- Christopher A. Potter (ORCID: https://orcid.org/0000-0003-1757-2550)
- Deborah Forst (ORCID: https://orcid.org/0000-0002-8428-0841)
- Elizabeth R. Gerstner (ORCID: https://orcid.org/0000-0003-2382-3838)
- Min Lang
- Albert Jiao (ORCID: https://orcid.org/0000-0003-3354-1850)
- Natalie Stec
Institutions
- Brigham and Women's Hospital (US)
- Children's Medical Center (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Southwestern Medical Center (US)
- Center for Neuro-Oncology (US)
- Dana-Farber Cancer Institute (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1093/noajnl/vdae227
- Citations
- 9
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.94
Funders
- Brigham and Women's Hospital
- Massachusetts General Hospital
- University of Texas Southwestern Medical Center